Sirolimus (rapamycin), an mTORC1 inhibitor, is FDA-approved (May 2015) and EMA-approved (...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-TSC1-LAM |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-05-04 | pending_clinical_signoff | actionability review required |
| Enfermedades | DIS-LAM |
| Fuentes | SRC-MILES-MCCORMACK-2011 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-TSC1 |
|---|---|
| Variante | TSC1 o TSC2 pérdida de función (contexto LAM — somático en LAM esporádico, línea germinal en Lam asociado a TSC); la hiperactivación mTORC1 es el objetivo terapéutico independientemente de la especificidad TSC 1 vs TSC 2 |
| Enfermedad | DIS-LAM |
| El nivel de ESCAT | IA |
| Combinaciones recomendadas | sirolimus (target trough 5–15 ng/mL; start 2 mg/day PO, adjust to trough; continuous indefinitely for progressive LAM), everolimus 10 mg PO QD (TSC-associated LAM and renal AML; EXIST-2 dosing) |
| Monoterapia contraindicada | sirolimus in pregnancy — embryo-fetal toxicity; mandatory contraception, hormonal contraceptives (estrogen-containing) — LAM is estrogen-sensitive; progesterone-only or non-hormonal methods preferred |
| Resumen de las pruebas | Sirolimus (rapamycin), an mTORC1 inhibitor, is FDA-approved (May 2015) and EMA-approved (2017) for treatment of LAM in adults. MILES phase III RCT (McCormack et al., NEJM 2011): N=89 (46 sirolimus, 43 placebo); 12-month treatment + 12-month observation. Primary endpoint: FEV1 change from baseline to 12 months (mL/month rate). FEV1 slope: +1 mL/month (sirolimus) vs -12 mL/month (placebo); difference 11 mL/month (p<0.001). Secondary: FVC improvement, VEGF-D reduction, 6-min walk improvement, QoL. After 12-month observation: benefits partially lost (FEV1 decline resumes), suggesting need for continuous therapy. mTOR inhibition does not eliminate LAM cells but controls their mTORC1-driven proliferation. Everolimus is used for TSC-associated LAM and for renal angiomyolipoma (EXIST-2). VEGF-D ≥800 pg/mL is a diagnostic biomarker (non-invasive diagnosis of LAM possible in right clinical context without biopsy). |
Notas
ESCAT IA (FDA-approved, phase III RCT). Sirolimus does not cure LAM — TSC1/TSC2-deficient LAM cells persist but their mTORC1-driven proliferation is suppressed. Therapy is indefinite. Monitoring: pulmonary function tests (PFTs) q3–6 months; HRCT annually or if symptoms change; sirolimus trough levels (target 5–15 ng/mL); VEGF-D (diagnostic and monitoring). Drug interactions: sirolimus is a CYP3A4 substrate and inhibitor — avoid strong CYP3A4 inhibitors (azoles increase sirolimus levels) and inducers (rifampin decreases levels). TSC-associated LAM vs sporadic LAM: clinical management identical; TSC patients also need surveillance for SEGA, renal AML (both everolimus-treatable), and other TSC manifestations. Lung transplantation: reserved for advanced LAM (FEV1 <40% predicted, significant hypoxemia); sirolimus is typically held peri-transplant (impairs healing) and restarted post-transplant in some centers.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.